Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...
Novavax a relevé jeudi, pour la troisième fois cette année, ses prévisions de chiffre d'affaires annuel, misant sur les ...
GAITHERSBURG, Md. - Novavax, Inc. (NASDAQ:NVAX) a finalisé le transfert de l’autorisation de commercialisation américaine de son vaccin COVID-19 Nuvaxovid à Sanofi, déclenchant un paiement d’étape de ...
Novavax, Inc. a annoncé avoir finalisé le transfert de l'autorisation de mise sur le marché américaine de son vaccin contre ...
Novavax expects 2026 adjusted revenue between $185 million and $205 million, excluding royalties and sales from its licensing ...
Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, ...
10d
Novavax Inc (NVAX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Challenges
Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.
Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.
Novavax (NVAX) officially handed over U.S. marketing rights for its COVID-19 vaccine, Nuvaxovid, to Sanofi. This milestone triggered a $25 million payment to Novavax and highlights progress in their ...
Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...
Discover Novavax's Q3 2025 earnings: partnership-driven strategy, cost savings, increased revenue outlook, and pipeline progress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback